Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1810 results
May 2017
-
Media Release
Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids
New analyses from the FLAME study suggest dual bronchodilator Ultibro® Breezhaler® provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type of… -
Media Release
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
Phase III trial, first-line treatment with Zykadia resulted in improved progression-free survival (PFS) over SOC chemotherapy with maintenance, including in patients with brain metastases[1]… -
Media Release
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care
Updated analyses from the Kisqali® pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be… -
Media Release
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
Better Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension… -
Story Discovery
Women in Science: Renee Rodgers
-
Story Access to Healthcare
Novartis invites scrutiny of effort to improve access to medicine
Public health expert Richard Laing discusses how independent measurement of access programs can help ensure their success
-
In The News
Novartis Access and government of Pakistan sign memorandum of understanding
Novartis reaches agreement with Pakistan to increase access to medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation. -
Media Release
Novartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communities
Community Partnership Day symbolizes the company's commitment to improving people's lives and serving our local communities Follow the excitement with #NovartisCPD2017 and #proudmoments2017 via… -
In The News
Novartis Access perspective: The key to fighting chronic disease in South-East Asia - young people
Harald Nusser, Head of Novartis Social Business, explains why educating young people is key to fighting chronic disease in South-East Asia. -
Story Discovery
Taking clinical trials to the next level through technology
Learn how Novartis is using technology to improve the oncology clinical trial process.
-
Media Release
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
Exclusive license for emricasan supports rapidly growing development portfolio in chronic liver diseases, including NASH Conatus has initiated the Phase IIb ENCORE-LF clinical trial with… -
In The News
Novartis Access perspective: How smart partnerships can help us fight chronic disease in Africa
Harald Nusser, Head of Novartis Social Business, talks about how the pharmaceutical industry can work with partners to overcome access issues in poor countries.